Navigation Links
New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
Date:5/30/2008

safety profile was similar in both groups with the majority of reported adverse events being mild or moderate local or systemic reactions(1).

Gene Profiling in Melanoma: abstract # 9045(2)

Gene expression profiling by microarrays was used to identify markers predictive of the clinical activity of the MAGE-A3 ASCI recorded in the phase II melanoma study. Gene expression profiling was performed on tumor biopsies taken prior to any immunization, leading to the identification of a gene signature which reflects a specific immune micro-environment present prior to any therapeutic intervention. This gene signature seems to be strongly associated with MAGE-A3-induced clinical responses(2).

Gene Profiling in Non-Small Cell Lung Cancer: abstract # 7501(3)

These data show that it may be possible to identify patients that present a high or low risk of relapse after surgery. A gene signature similar to that observed in melanoma was associated in a retrospective analysis with a lower rate of disease recurrence in the MAGE-A3 treated group. Another signature that is predictive to clinical activity of the MAGE-3 ASCI treatment, which increased clinical activity by a factor of 2, was also described(3).

This specific set of data follows the proof of concept Phase II data that GSK reported at ASCO in 2007, which showed a 27% reduction in the relative risk of NSCLC recurrence following surgery in patients treated with the MAGE-A3 ASCI, compared to placebo(4). In the patients population selected for the presence of the predictive gene signature, a 43% reduction in the relative risk of relapse was observed(3). (Data on file).

Based on these encouraging data in NSCLC, GSK has initiated patient recruitment to a randomized and controlled Phase III efficacy and safety trial (MAGRIT) for this novel cancer immunotherapy. MAGE-A3 ASCI will be evaluated as adjuvant therapy in about 2,270 MAGE-A3-positive patients with completely resected stage IB, II or
'/>"/>

SOURCE GlaxoSmithKline (GSK)
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Presentation of Data on Progens Cancer Epigenetic Targets Platform
2. Genmab Announces Updates on Phase III Cancer Studies
3. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
4. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
5. BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer
6. Prostate Cancer Treatment Offers Results Without Side Effects
7. TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
8. First Patient Enrolled in Global Phase III Study of Bevacizumab and Trastuzumab in Early Breast Cancer
9. Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy
10. Exiqon Forms Research Collaboration With M. D. Anderson Cancer Center
11. Ovarian Cancer Vaccine Clinical Trial Begins at Cancer Treatment Centers of America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... and NEW YORK , ... of the executive management team of Caremark Rx, ... Media ( www.pbm365.com ).  PBM365 is the leading independent ... reporting, insight, analysis and opinion on the pharmacy ... will provide insightful and timely coverage of, and context ...
(Date:7/29/2014)... 2014 According to a new ... Fixation Devices Market - Global Forecast, Market Share, Size, ... orthopedic trauma fixation devices market is estimated at USD ... at a CAGR of 7.2% from 2014 to 2019, ... in 2020. Browse the Orthopedic Trauma Fixation ...
(Date:7/29/2014)... -- Research and Markets has announced the ... report to their offering. ... a medical device used to provide medication or assist ... cannot achieve adequate oxygen levels to maintain life. Patients ... and ARDS require the need of respiratory devices. The ...
Breaking Medicine Technology:Drew Crawford Announces Launch of PBM365 Media 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 3Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 4Global Respiratory Devices Market 2014-2018 2
... May 19 A meta-analysis of approximately ... The Lancet on May 1, 2010 ... phospholipase A2 (Lp-PLA2), a vascular-specific inflammatory enzyme, are associated ... in magnitude to that with non-HDL cholesterol or systolic ...
... SAN FRANCISCO , May 19 ... trials evaluating Ferring Pharmaceuticals, LYSTEDA™ (tranexamic acid) tablets, a ... with cyclic heavy menstrual bleeding (HMB), were presented at ... Clinical Meeting in San Francisco , May ...
Cached Medicine Technology:Large Meta-Analysis Further Validates Benefit of Measuring Lp-PLA2 for Coronary Heart Disease and Ischemic Stroke Risk Assessment 2Large Meta-Analysis Further Validates Benefit of Measuring Lp-PLA2 for Coronary Heart Disease and Ischemic Stroke Risk Assessment 3Clinical Data Demonstrates That LYSTEDA™ Significantly Reduced Menstrual Blood Loss and Limitations on Social, Leisure and Physical Activities in Women With Cyclic HMB 2Clinical Data Demonstrates That LYSTEDA™ Significantly Reduced Menstrual Blood Loss and Limitations on Social, Leisure and Physical Activities in Women With Cyclic HMB 3Clinical Data Demonstrates That LYSTEDA™ Significantly Reduced Menstrual Blood Loss and Limitations on Social, Leisure and Physical Activities in Women With Cyclic HMB 4Clinical Data Demonstrates That LYSTEDA™ Significantly Reduced Menstrual Blood Loss and Limitations on Social, Leisure and Physical Activities in Women With Cyclic HMB 5Clinical Data Demonstrates That LYSTEDA™ Significantly Reduced Menstrual Blood Loss and Limitations on Social, Leisure and Physical Activities in Women With Cyclic HMB 6
(Date:7/29/2014)... Denver, Colorado (PRWEB) July 29, 2014 Daily ... the author of this program claims that he cured his ... the author decided to share part of his experience. ... nasal polys permanently and naturally in just 4 days. Since ... share it with sufferers from all around the world. ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Daily Gossip indicates ... new method was created for any sufferer who is looking ... , The author of the new program, Sarah Summer, says ... actually suffered from yeast infection, too. Actually, this is the ... for this problem. , The Natural Cure for ...
(Date:7/29/2014)... For numerous women from all over the world, finding ... being quite hard. Well, the author of the Make Him ... can help all these women. This is the formula that ... and attention every day. , Daily Gossip reveals in ... Alex Carter who published a unique eBook to detail it. ...
(Date:7/29/2014)... Recent international changes to the ... Nurse Call Systems to be considered medical devices. ... Nurse Call Systems to be clinically regulated, audited ... reduces clinical risks, and is good news for ... and Clinical Risk Committee actively pursuing corporate governance. ...
(Date:7/29/2014)... Daily Gossip reveals in its review that the Tinnitus Miracle ... eliminate all the symptoms associated to this condition. , ... such as mild hearing loss, as well as headaches. The ... gone forever. , The method will lead to a cure ... says that at the end of the treatment, sufferers will ...
Breaking Medicine News(10 mins):Health News:Nasal Polyps Treatment Miracle Review Reveals How to Cure Nasal Polyps Without Surgery 2Health News:Natural Cure for Yeast Infection Review Reveals Sarah Summer’s Healing Method 2Health News:"Make Him Desire You" Review Reveals Unique Formula to Make Men Feel a Special Kind of Love 2Health News:NiQ Health Reveals the Extensive Use of Unregulated Medical Devices in Australian Hospitals 2Health News:NiQ Health Reveals the Extensive Use of Unregulated Medical Devices in Australian Hospitals 3Health News:NiQ Health Reveals the Extensive Use of Unregulated Medical Devices in Australian Hospitals 4Health News:Tinnitus Miracle Review Exposes the Only Holistic System for Tinnitus Cure 2
... ,Using the male chromosome as a marker, researchers studying ... have discovered that the body can actively reshape the ... that the heart cannot repair itself and the finding ... realization that the body works to repair a damaged ...
... patients on long-term non-steroidal anti-inflammatory drug (NSAID) treatment ... can substantially reduce the risk of ulcer formation.// ... cent of H.pylori infections and reduced the six-month ... the control group to 12 per cent in ...
... say they have discovered molecules in the body ... free radicals.With further research, the research could potentially ... Oxidative damage has been linked with ailments such ... and diabetes, cancer and Alzheimer’s disease. ...
... a steroid nasal spray may relieve seasonal ... Dr. Robert Naclerio and colleagues from University ... nasal spray, with loratadine(Claritin),a nonsedating antihistamine, for ... , Participants who used the inhaled ...
... way to slow down the respiration rate. Just by practising ... can be slowed down and thereby calm the heart rhythm. ... ritual in the Catholic Church - and the benefits may ... Cleavland, recorded breathing rates during normal talking and recitation of ...
... from asthma, particularly women, may have an increased risk ... years, researchers studied almost 100,000 patients who had been ... showed any signs of cancer at their initial assessment. ... asthma diagnosis until the last day of the three-decade ...
Cached Medicine News:
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: